Dr Sidney Norman Kahn, MB, CHB in Wyncote, PA - Pathology

Dr Sidney Norman Kahn, MB, CHB is a Pathology - Chemical Pathology physician based in Wyncote, Pennsylvania. Dr Sidney Norman Kahn is licensed to practice in Pennsylvania (license number MD037772E) and his current practice location is 401 Crescent Rd, Wyncote, Pennsylvania. He can be reached at his office (for appointments etc.) via phone at (215) 885-0212.

NPI number for Dr Sidney Norman Kahn is 1952635955 and his current mailing address is 401 Crescent Rd, Wyncote, Pennsylvania. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1952635955.

Contact Information

	Dr Sidney Norman Kahn, MB, CHB
	401 Crescent Rd, Wyncote, PA 19095-1702
	(215) 885-0212
	(215) 885-0213

Physician's Profile

Full Name	Dr Sidney Norman Kahn
Gender	Male
Speciality	Pathology - Chemical Pathology
Location	401 Crescent Rd, Wyncote, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1952635955
Provider Enumeration Date: 09/23/2009
Last Update Date: 09/23/2009

Medical Identifiers

Medical identifiers for Dr Sidney Norman Kahn such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1952635955	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZP0104X	Pathology - Chemical Pathology	MD037772E (Pennsylvania)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Sidney Norman Kahn is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Sidney Norman Kahn, MB, CHB 401 Crescent Rd, Wyncote, PA 19095-1702 Ph: (215) 885-0212	Dr Sidney Norman Kahn, MB, CHB 401 Crescent Rd, Wyncote, PA 19095-1702 Ph: (215) 885-0212

News Archive

Trius prices 10,000,000 shares initial public offering

Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.

IPS examines malnutrition, obesity in Latin America

Inter Press Service examines malnutrition and factors contributing to the rising rates of "obesity and obesity-related illness - such as type II diabetes, high blood pressure, heart disease, some forms of cancer and osteoporosis - in Latin America, and especially among the poorest sectors of the population."

Adopting pharmacy carve-in approach can help 13 states realize over $11 billion savings in Medicaid

A study sponsored by Medicaid Health Plans of America (MHPA) released today by The Lewin Group finds large-scale savings can be achieved if 13 states abandoned their current pharmacy carve-out model in favor of a carve-in approach - including prescription drugs in health plans' capitation payments.

Santen Pharmaceutical and jCyte conclude an exclusive licensing contract in Japan, Asia and Europe for the jCell therapy programme for retinitis pigmentosa

Santen Pharmaceutical Co., Ltd. and jCyte Inc. announced the conclusion of an exclusive licensing contract covering the development, registration and commercialisation rights in Japan, Asia and Europe to jCell, a first-in-class investigational therapy, currently in clinical development for retinitis pigmentosa.

Dr Sidney Norman Kahn, MB, CHB - Pathology in Wyncote, PA